Academic Geriatric Medicine, Southampton General Hospital Mailpoint 807, University of Southampton, Southampton, SO16 6YD, UK.
Eur Geriatr Med. 2020 Dec;11(6):975-993. doi: 10.1007/s41999-020-00396-x. Epub 2020 Sep 24.
Research evaluating the effect of probiotics, prebiotics and synbiotics (PPS) on laboratory markers of health (such as immunomodulatory and microbiota changes) is growing but it is unclear whether these markers translate to improved functional outcomes in the older population. This systematic review evaluates the effect of PPS on functional outcomes in older people.
We conducted a systematic review of the effect of PPS in older adults on functional outcomes (physical strength, frailty, mood and cognition, mortality and receipt of care). Four electronic databases were searched for studies published since year 2000.
Eighteen studies (including 15 RCTs) were identified. One of five studies evaluating physical function reported benefit (improved grip strength). Two analyses of one prebiotic RCT assessed frailty by different methods with mixed results. Four studies evaluated mood with no benefit reported. Six studies evaluated cognition: four reported cognitive improvement in participants with pre-existing cognitive impairment receiving probiotics. Seven studies reported mortality as a secondary outcome with a trend to reduction in only one. Five studies reported length of hospital stay but only two peri-operative studies reported shorter stays.
There is limited evidence that probiotics may improve cognition in older people with pre-existing cognitive impairment but no clear evidence of benefit of PPS on physical function, frailty, mood, length of hospitalisation and mortality. Larger studies with more homogenous interventions, accounting for confounding factors, such as diet, co-morbidities and medications, are required. There is currently inadequate evidence to recommend PPS use to older people in general.
PROSPERO registration number is CRD42020173417. Date of PROSPERO registration: 01/05/20.
评估益生菌、益生元和合生剂(PPS)对健康实验室指标(如免疫调节和微生物群变化)影响的研究正在不断增加,但尚不清楚这些标志物是否能转化为改善老年人的功能结局。本系统评价评估了 PPS 对老年人功能结局的影响。
我们对 2000 年以来发表的 PPS 对老年人功能结局(体力、虚弱、情绪和认知、死亡率和护理)影响的研究进行了系统评价。我们在四个电子数据库中搜索了研究。
确定了 18 项研究(包括 15 项 RCT)。五项评估身体功能的研究中有一项报告了获益(握力增强)。一项益生元 RCT 的两项分析采用不同方法评估虚弱,结果不一致。四项研究评估了情绪,但没有报告获益。六项研究评估了认知:四项研究报告了接受益生菌的有预先存在认知障碍的参与者认知改善。有七项研究报告了死亡率作为次要结局,只有一项显示出降低的趋势。五项研究报告了住院时间,但只有两项围手术期研究报告了较短的住院时间。
有限的证据表明,益生菌可能改善老年人的认知功能,但 PPS 对体力、虚弱、情绪、住院时间和死亡率没有明显益处。需要进行更大规模、更同质的干预研究,考虑饮食、合并症和药物等混杂因素。目前尚无足够证据推荐 PPS 一般用于老年人。
PROSPERO 注册号:PROSPERO 注册号是 CRD42020173417。PROSPERO 注册日期:2023 年 5 月 1 日。